Background/Aims: Increasing evidence has shown that miR-216b plays an important role in human cancer progression. However, little is known about the function of miR-216b in renal cell carcinoma. Methods: The expression levels of miR-216b in renal cell carcinoma tissues and cell lines were examined by qRT-PCR. The biological role of miR-216b in renal cell carcinoma proliferation and/or metastasis was examined in vitro and in vivo. The target of miR-216b was identified by a dual-luciferase reporter assay. The expression level of KRAS protein was measured by western blotting. Results: The expression of miR-216b was downregulated in clear cell renal cell carcinoma (ccRCC) cell lines and specimens compared to the adjacent normal tissues. Furthermore, miR-216b can bind to the 3'untranslated region (UTR) of KRAS and inhibit the expression of KRAS through translational repression. The in vitro study revealed that miR-216b attenuated ccRCC cell proliferation and invasion. Furthermore, in vivo study also showed that miR-216b suppressed tumor growth. MiR-216b exerted its tumor suppressor function through inhibiting the KRAS-related MAPK/ERK and PI3K/AKT pathways. Conclusion: Our findings provide, for the first time, significant clues regarding the role of miR-216b as a tumor suppressor by targeting KRAS in ccRCC.
.
Construct of Luciferase reporter vectors and KRAS-expressing vector
The full-length KRAS 3'-UTR was cloned into the Sac I and Mlu I sites of the pSicheck-2 luciferase vector using the PCR generated fragment. The mutant vector pSi-KRAS mut in which the first five nucleotides complementary to the miR-216b seed-region were mutated by site-directed mutagenesis, was constructed as a mutant control. Fulllength KRAS cDNA entirely without the 3'-UTR was purchased from Origen (Rockville, MD, USA) and subcloned into the eukaryotic expression vector pCMV-Entry vector. The primers used in this study are shown in Table 1 . The empty pCMV-Entry vector was used as a negative control.
Cell transfection
For the function experiments of miR-216b, the miR-216b mimics and the negative scramble control were transfected into 786-O and ACHN cells using Lipofectamine 3000 (Invitrogen). The inhibitors antimiR216b and anti-scramble were also transfected into 786-O and ACHN cells. For miRNA and pCMV-KRAS combination experiments, 786-O and ACHN cells were transfected with pCMV-KRAS or empty vector 24 hours together with miR-216b mimics or inhibitors.
Dual Luciferase assay pSi-KRAS wt and pSi-KRAS mut were co-transfected with miR-216b mimics into 786-O cells. Luciferase activity was measured in cell lysates 48 hours after transfection using the Dual-luciferase reporter gene assay kit (Promega). Results were normalized against b-galactosidase activity.
Protein Analysis
Western blotting was carried out as described [15] . Anti-KRAS antibody was obtained from SigmaAldrich. Antibodies against ERK, phosphorylated ERK, AKT and phosphorylated AKT antibodies were obtained from Cell Signaling Technology. Anti-β-tubulin antibody was from abcam.
Cell proliferation assay
After transfection, cells were plated into 96-well plates at the desired cell concentrations. Cells were analyzed at 0, 24, 48 and 72 hours using the Cell Counting kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) with a Coulter counter (Beckman Coulter, Fullerton, CA) at the indicated time points.
Cell invasion assay
At 48 hours after transfection, cells were seeded onto the basement membrane matrix (EC matrix, Chemicon, Temecula, CA) present in the insert of a 24-well culture plate. Complete culture medium was added to the lower chamber as a chemoattractant. After a further 24 hours, the non-invading cells and EC matrix were gently removed with a cotton swab. Invasive cells located on the lower side of the chamber were fixed with 4% paraformaldehyde and stained with Crystal Violet, air-dried and photographed with microscope (Nikon Elipse Ci, Japan). In vivo animal model For the subcutaneous tumor growth assay, 2 x 10 6 cells were suspended in 0.1 ml of PBS and implanted subcutaneously into the flanks of six-week-old male balb/c nu-nu mice. Tumor growth was examined twice a week, and tumor volume was estimated by the formula LW 2 /2, where L is the length and W is the width of the tumor. Tumor weight was measured at the end of the study. All animal procedures were performed with the approval of the Ethical Committee of Shenzhen hospital, Peking University, China.
Statistical Analysis
All experiments were performed in triplicate. The data were statistically evaluated by analysis (ANOVA) and comparison means (student's t-test). A p value of less than 0.05 indicated the presence of statistically significant difference between groups. All statistical analyses were carried out with Graphpad Prism 6.
Results

MiR-216b is downregulated in ccRCC cell lines and clinical specimens
In our previous study, miR-216b was found to be downregulated in ccRCC specimens as assessed by microarray analysis [16] . Here we identified the expression of miR-216b both in 31 ccRCC and in specimens by qPCR. MiR-216b was reduced in clinical ccRCC specimens compared to the matched adjacent normal specimens ( Fig. 1A and B, p<0.001). Cellular Physiology and Biochemistry
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To study the role of miRNA in the progress of ccRCC, we analyzed the different expression of miR-216b in five ccRCC cell lines by qPCR. The lower expression of miR-216b was found in 786-O and ACHN cell lines compared to that in other three cell lines: namely 769-P, Caki-1 and Caki-2 ( Fig. 1C) . Therefore, 786-O and ACHN were selected for subsequent function studies.
To investigate the role of miR-216b, we transfected miR-216b mimics or inhibitors in 786-O and ACHN to increase or decrease the expression level of miR-216b. The qPCR results revealed that miR-216b was increased markedly by introducing miR-216b mimics (Fig. 1E and F, p<0.001). But miR-216b inhibitors did not exert its function on the endogenous miR216b (Data not shown). It might be the cause of the too low expression of miR-216b in ccRCC cells.
MiR-216b directly targets and inhibits KRAS
To explore the function of miR-216b, three computational algorithms: TargetScan, PicTar and miRanda, were used to search for potential miR-216b target genes and a large number of different target genes were predicted. In addition, in our preliminary next sequencing results [16] , six genes (KRAS, BCL11B, CSK, RP2, ZFC3H1 and RPGRIP1L) were analyzed as targets of miR-216b. Combining these two sets of data, KRAS attracted our attention immediately. KRAS was a master regulator of cell growth, proliferation, differentiation and carcinogenesis. We detected KRAS protein level in ten pairs of clinical clear cell renal cell carcinoma specimens and adjacent specimens. It was observed that KRAS was dramatically upregulated in six ccRCC tissues (Fig. 1D) . In addition, a miR-216b-binding site was found in the 3'-UTR of KRAS mRNA. There was perfect base pairing between the seed sequence 
of mature miR-216b and the 3'-UTR of KRAS mRNA ( Fig. 2A) . To verify whether KRAS is a direct target of miR-216b, we subcloned the sequences of KRAS 3'-UTR into a luciferase reporter vector pSicheck-2. It showed that addition of miR-216b dramatically suppressed the luciferase activity of the KRAS 3'-UTR upon co-transfection of the luciferase vector (wildtype or mutant) with miR-216b into ccRCC cells (Fig. 2B, p<0 .05). To directly assess the effect of miR-216b on KRAS expression, we transfected miR-216b into 786-O or ACHN cells and found that overexpression of miR-216b reduced KRAS protein levels (Fig. 2D) . Much to our surprise, overexpression of miR-216b did not affect KRAS mRNA levels (Fig. 2C) Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry intracellular levels of miR-216b were altered significantly after treatment with miR-216b mimics ( Fig. 1E and F, p<0 .001). These results provide evidence that miR-216b directly binds to the 3'-UTR of KRAS mRNA and inhibits KRAS protein translation.
MiR-216b suppresses cell proliferation and invasion by targeting KRAS
In light of the above findings, we decided to explore the biological significance of miR216b in ccRCC tumorigenesis. We found that overexpression of miR-216b in 786-O and ACHN cells markedly attenuated cell proliferation (Fig. 3A and B) and that the restoration of KRAS (without an endogenous 3'-UTR) rescued this inhibition (Fig. 3C and D) , suggesting that miR-216b targets KRAS specifically. The overexpression of miR-216b inhibited the cell invasive potentials of 786-O and ACHN cells (Fig. 3E and F) , whereas re-expression of KRAS rescued this inhibition ( Fig. 3G and H ). Our findings demonstrate that miR-216b has properties consistent with tumor suppressor function. The ability to modulate KRAS protein levels might explain, at least in part, why miR-216b can inhibit cell proliferation and invasion in ccRCC.
Next we used the subcutaneous xenograft mouse models to assess the impact of miR216b in tumor growth in vivo. The ACHN cells with agomir-216b or negative scramble control were subcutaneously injected into the flanks of balb/c nu-nu mice, and the tumor volumes were measured twice a week. At 42 days after implantation, the mice were sacrificed. The agomir-216b group exhibited a significant reduction in both tumor volume and weight compared with those of the negative control group (Fig. 4A-C) . These data suggest that miR216b inhibits tumor growth of ccRCC in vivo.
MiR-216b inhibits the AKT and ERKs pathways
KRAS activation can trigger several important signaling pathways, such as the PI3K/ AKT and MAPK/ERK pathways, most of which regulate cell proliferation and invasion [17] [18] [19] [20] . Therefore, we investigated the possibility that miR-216b regulates those pathways by targeting KRAS. Restore of miR-216b, through transfection of miR-216b mimics, in 786-O and ACHN cells decreased the phosphorylation levels of AKT (Fig. 5A) . Similarly, miR-216b suppressed the levels of phosphorylated ERK (Fig. 5A) . These western blotting results demonstrate that miR-216b is a negative regulator of AKT and ERK pathways. Subsequently, rescue experiments were performed by overexpressing the KRAS vector (without an endogenous 3'-UTR) in miR-216b-treated cells: 786-O or ACHN cells were Cell
co-transfected with miR-216b mimics and KRAS-encoding vector (pCMV-KRAS).
The miR216b-induced downregulation of KRAS was rescued upon the introduction of KRAS, and the phosphorylation levels of AKT and ERK were altered in a similar manner (Fig. 5B) . The downregulation of phosphorylated AKT and phosphorylated ERK by miR-216b could be rescued by re-expression of KRAS (Fig. 5B ). These observations suggest that miR-216b inhibits the AKT and ERK pathways by targeting KRAS.
Discussion
Until now, only a handful of studies have identified specific miRNAs involved in human ccRCC tumorigenesis and metastasis. Therefore, we believe more effort should be made, not only towards the identification of relevant miRNAs but also into the specific mechanisms by which they accomplish their specific functions, particularly with regard to the oncogenesis of different types of tumors. Ding et al. found that miR-367 expression was increased in both human ccRCC tissues and cell lines and that ectopic high expression of miR-367 could promote cell proliferation and metastasis by targeting metastasis associated protein 3 (MTA3) in ccRCC [21] . Yoshino H et al. reported that miR-210-3p was downregulated in ccRCC, and the deletion of miR-210-3p promoted tumorigenesis through revival of TWIST1 [22] .
In a preliminary study, we found miR-216b was downregulated in 10 ccRCC tissues compared with the matched adjacent normal tissues by miRNA sequencing [16] . Here, we used qRT-PCR to assess the level of miR-216b in ccRCC cell lines and 31 clinical specimens and found that miR-216b was indeed downregulated in ccRCC (Fig. 1A and B) . In addition, we have shown that ectopic expression of miR-216b is associated with ccRCC cell growth and metastasis (Fig. 3A-H) . Furthermore, we explored the potential targets of miR-216b in ccRCC cells via three miRNA target predict tools, and concerned the preliminary data also. It revealed KRAS as a candidate target of miR-216b, which attracted our attention immediately. Like other members of the RAS family, KRAS is a GTPase and an early player in many signal transduction pathways. Active GTP-bound KRAS associates with a wide variety of effectors, including Raf, PI3K, Ral-GDS, Rho GTPases and other molecules, to transmit downstream signals controlling distinct cellular events, including cell proliferation, survival, differentiation and invasion [17, 23] . Interestingly, KRAS gene mutations are rare in breast cancer [24] and nasopharyngeal carcinoma [25] , but its upregulation has been found in these tumors analyzed [26] [27] [28] [29] . The same situation has been observed in renal cell carcinomas. Hence, KRAS mutations do not appear to play a major role in these types of tumors [13] , but several studies have revealed that KRAS overexpression is a frequent event in these tumors [14] . Here, restoration of miR-216b inhibits KRAS protein level in ccRCC cells (Fig. 2D) . Moreover, the luciferase activity assays demonstrated that miR-216b could bind to the 3'-UTR of KRAS mRNA (Fig. 2B) . All of these data suggest that miR-216b directly targets KRAS expression in ccRCC cells. MiRNAs regulate gene expression through suppressing translation or inducing degradation of the target mRNAs. In the current study, we also investigated the effect of miR-216b on KRAS mRNA levels and found that miR-216b did not modulate KRAS mRNA levels (Fig. 2C) . This implies that miR-216b targets KRAS through inhibiting translation, not by degrading mRNA. KRAS has been shown to be activated in various tumor types. It is well known that active RAS transduces signals from cell surface receptors into the cytoplasm through specific effector pathways and regulates diverse cellular processes. The classic pathways downstream of KRAS are the MAPK/ERK and PI3K/AKT pathways [17, 19] . The ability to target KRAS transcripts signifies that miR-216b might be a potential regulator of the MEK/ ERK and PI3K/AKT pathways in ccRCC cells. Our results have demonstrated that miR-216b can inhibit the constitutive activity of AKT and ERK pathways through targeting KRAS (Fig.  5A ), whereas expression of exogenous KRAS (without an endogenous 3'-UTR) can rescue this inhibition (Fig. 5B) . Given that KRAS plays a significant role in the regulation of cell proliferation and invasion, we investigated the effect of miR-216b on these phenotypes of ccRCC cells. MiR-216b overexpression in 786-O and ACHN cells markedly attenuated the ability of the cells to proliferate and invade (Fig. 3A, B, E and F, Fig. 4 A-C), whereas overexpression of KRAS (without an endogenous 3'-UTR) rescued the inhibition of cell growth and the invasion caused by miR-216b, suggesting target specificity (Fig. 3C, D , G and H). KRAS is an upstream modulator of many pathways, including AKT and ERK, through which it controls cell proliferation and invasion. Our findings suggest that miR-216b functions as a tumor suppressor, affecting ccRCC cell proliferation and invasion by targeting KRAS and subsequently suppressing downstream AKT and ERK signaling pathways. However, to completely clarify the function of miR-216b in tumorigenesis, more candidate targets will have to be detected in more types of cancers.
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